New medicine for two types of pulmonary fibrosis
WHY IT MATTERS
Patients with idiopathic pulmonary fibrosis in the EU now have access to a newly approved treatment option that may help slow lung scarring and preserve breathing ability.
The European Medicines Agency has approved a new medicine called Jascayd (nerandomilast) to treat adults with two types of lung scarring diseases: idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease. This approval means the medicine is now available for patients in the European Union. This is the first time this particular medicine has been approved for these conditions in Europe.
Source: European Medicines Agency (EMA) Description: EMA has recommended granting a marketing authorisation in the European Union (EU) for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) or… Published: 2026-05-22T10:00:01.000Z Note: EMA announcements cover medicines approved in the EU. Orphan designations may not yet be available in the US.
ASK YOUR DOCTOR
If you have idiopathic pulmonary fibrosis or progressive fibrosing interstitial lung disease and live in the EU, ask your doctor at your next appointment whether Jascayd might be appropriate for your treatment plan.